The Oligonucleotide Synthesis Facility was established in response to the need to provide quality synthetic oligonucleotides to the University of Pittsburgh Cancer Institute (UPCI) members and other investigators in the Pittsburgh research community. The Facility arose from a demonstrated need for oligonulceotides in projects ranging from molecular biology to macromolecular crystallography. The Facility offers both crude and purified oligonucleotides at the 0.05, 0.2 and 1 micromole scales. The yield for each synthesis is assayed and the DNA is dissolved in water, ready for use by the investigator. A DNA Synthesis Advisory Committee, including members of the UPCI, was established to oversee the operation of the Facility. This committee meets yearly to review the performance of the Facility, establish user fees and set protocols to keep the Facility running efficiently. Dr. Graham Hatfull, Chairman of the Department of Biological Sciences, University of Pittsburgh, is the director. He is a renowned molecular biologist and a member of the Molecular and Cellular Oncology Program (need to verify this!). The daily operations such as performing the syntheses, data analysis, quality control and maintenance procedures are carried out by manager, Patricia Wells Gruber and the research specialist, David Close. The Facility can generate high purity oligonucteotidcs quickly and at a reasonable cost. Chemical costs have been progressively discomated in response to the increased volume of orders. The quality, cost and rapid turnaround time make this facility a vital part of the research community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-17
Application #
6989543
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-22
Project End
2009-07-31
Budget Start
2004-09-22
Budget End
2005-07-31
Support Year
17
Fiscal Year
2004
Total Cost
$27,599
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478

Showing the most recent 10 out of 1187 publications